These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 33882227)

  • 1. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply.
    Barda N; Dagan N; Balicer RD
    N Engl J Med; 2021 May; 384(20):1970. PubMed ID: 33882227
    [No Abstract]   [Full Text] [Related]  

  • 2. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
    Roest S; Hoek RAS; Manintveld OC
    N Engl J Med; 2021 May; 384(20):1968-1970. PubMed ID: 33882226
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply.
    Absalon J; Koury K; Gruber WC
    N Engl J Med; 2021 Apr; 384(16):1578. PubMed ID: 33596351
    [No Abstract]   [Full Text] [Related]  

  • 4. The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout.
    Zaqout A; Daghfal J; Alaqad I; Hussein SAN; Aldushain A; Almaslamani MA; Abukhattab M; Omrani AS
    Int J Infect Dis; 2021 Jul; 108():116-118. PubMed ID: 33992763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalisation amongst older people: matched case control study for England.
    Mason TFD; Whitston M; Hodgson J; Watkinson RE; Lau YS; Abdulrazeg O; Sutton M
    BMC Med; 2021 Oct; 19(1):275. PubMed ID: 34663326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won.
    Torreggiani M; Blanchi S; Fois A; Fessi H; Piccoli GB
    Kidney Int; 2021 Jun; 99(6):1494-1496. PubMed ID: 33887320
    [No Abstract]   [Full Text] [Related]  

  • 7. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.
    Amit S; Regev-Yochay G; Afek A; Kreiss Y; Leshem E
    Lancet; 2021 Mar; 397(10277):875-877. PubMed ID: 33610193
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
    Skowronski DM; De Serres G
    N Engl J Med; 2021 Apr; 384(16):1576-1577. PubMed ID: 33596348
    [No Abstract]   [Full Text] [Related]  

  • 9. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.
    Gobbi F; Buonfrate D; Moro L; Rodari P; Piubelli C; Caldrer S; Riccetti S; Sinigaglia A; Barzon L
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33807957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers.
    Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi GL; Lippi G
    J Infect; 2021 Aug; 83(2):e4-e5. PubMed ID: 34214516
    [No Abstract]   [Full Text] [Related]  

  • 12. Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients.
    Yanay NB; Freiman S; Shapira M; Wishahi S; Hamze M; Elhaj M; Zaher M; Armaly Z
    Kidney Int; 2021 Jun; 99(6):1496-1498. PubMed ID: 33887318
    [No Abstract]   [Full Text] [Related]  

  • 13. High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data.
    Hashimoto T; Ozaki A; Bhandari D; Sawano T; Sah R; Tanimoto T
    J Travel Med; 2021 Oct; 28(7):. PubMed ID: 34128049
    [No Abstract]   [Full Text] [Related]  

  • 14. Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost.
    Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
    Kidney Int; 2021 Dec; 100(6):1334-1335. PubMed ID: 34656642
    [No Abstract]   [Full Text] [Related]  

  • 15. Comment on: Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series: reply.
    Furer V; Zisman D; Elkayam O
    Rheumatology (Oxford); 2021 Dec; 61(1):e30. PubMed ID: 34554242
    [No Abstract]   [Full Text] [Related]  

  • 16. Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. 'COVID-arm': a clinical and histological characterization.
    Fernandez-Nieto D; Hammerle J; Fernandez-Escribano M; Moreno-Del Real CM; Garcia-Abellas P; Carretero-Barrio I; Solano-Solares E; de-la-Hoz-Caballer B; Jimenez-Cauhe J; Ortega-Quijano D; Fernandez-Guarino M
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e425-e427. PubMed ID: 33783873
    [No Abstract]   [Full Text] [Related]  

  • 17. A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2.
    Dickey JB; Albert E; Badr M; Laraja KM; Sena LM; Gerson DS; Saucedo JE; Qureshi W; Aurigemma GP
    JACC Cardiovasc Imaging; 2021 Sep; 14(9):1862-1863. PubMed ID: 34246585
    [No Abstract]   [Full Text] [Related]  

  • 18. [Development of thrombocytopenic purpura following BNT162b2 mRNA COVID-19 vaccination].
    Shibata K; Tanaka H; Otani A; Kubo M; Hasegawa A; Amano I
    Rinsho Ketsueki; 2021; 62(10):1519-1521. PubMed ID: 34732627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-episodic angioedema with eosinophilia after BNT162b2 mRNA COVID-19 vaccination.
    Ishizuka K; Katayama K; Kaji Y; Tawara J; Ohira Y
    QJM; 2021 Dec; 114(10):745-746. PubMed ID: 34546346
    [No Abstract]   [Full Text] [Related]  

  • 20. [Current state of vaccination against SARS-CoV-2].
    Iking-Konert C; Specker C; Krüger K; Schulze-Koops H; Aries P
    Z Rheumatol; 2021 Mar; 80(2):158-164. PubMed ID: 33528655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.